The Galleri blood test will begin trial by the National Health Service (NHS) with 165,000 patients after research found that it may reveal over 50 types of cancer. Some of these cancers are otherwise difficult to detect early.

If successful, the test could revolutionize early cancer diagnosis and potentially save many lives by identifying symptoms early enough to make the difference between life and death. If the patient is diagnosed while still in stage one, they’re survival rate jumps between 5-10 times higher than when it’s found at stage four.

Sir Simon Stevens, chief executive of NHS England, said: “While the good news is that cancer survival is now at a record high, over 1,000 people every day are newly diagnosed with cancer.

“Early detection – particularly for hard-to-treat conditions like ovarian and pancreatic cancer – has the potential to save many lives.” He said.

The test trial will begin mid-2021 and will be given to patients between 50 and 79 who have no symptoms. Then they will receive annual blood tests for three years.

Patients will be identified through NHS records, and anyone with a positive test will be referred to the health service for further investigation.

A further 25,000 people who have possible cancer symptoms will also take part and will be offered blood tests to help speed up their diagnoses after they have been referred to a hospital.

Results are expected by 2023, with a view to a wider roll-out in 2024 and 2025.

Written by: Ady Baddley